A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Trial Profile

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Idiopathic pulmonary fibrosis; Pneumonia; Pulmonary arterial hypertension; Sarcoidosis
  • Focus Therapeutic Use
  • Acronyms LARIAT
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2017 This study has been Discontinued in Spain.
    • 24 May 2017 Results of an interim analysis from expanded connective tissue disease patients (n=22) presented at the 113th International Conference of the American Thoracic Society
    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, based on the data of an analysis assessing risk factors and its risk mitigation strategy for managing acute fluid retention from BEACON trial, FDA approved the Phase 2 program in PAH (LARIAT). Data from CATALYST and LARIAT trials will be utilized for a New Drug Application review of the safety profile of the drug.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top